

## IPF, COMORBIDITIES AND MANAGEMENT IMPLICATIONS: PATIENT CASE 2

*Ole Hilberg*

Århus Universitetshospital, Århus, Denmark

### PATIENT PRESENTATION AND DIAGNOSIS

The patient is a 50-year-old woman who was referred to a tertiary centre with an HRCT showing definite UIP and a 6-minute walking distance of 145 metres. She was severely ill at presentation with a diffusion capacity of just 20%.


The patient had a history of peripheral arterial disease and had undergone both aortofemoral and femoro-femoral bypass due to arteriosclerosis and gluteal ischaemia. She also was suffering from renal impairment and had recently quit smoking.

### MANAGEMENT AND FOLLOW-UP

A request for lung transplantation was declined at three different centres owing to multiple comorbidities – namely, arteriosclerosis, impaired renal function, morphine therapy, and high blood pressure in the pulmonary circulation. Her lung function was stabilised for 6 months on pirfenidone, but repeat HRCT showed progressive lung disease (Figure 1).

### CONCLUSION

This case illustrates how comorbidity can influence treatment options in IPF and the importance of selecting the right patient for transplantation (1). Treatment with pirfenidone may improve the dis-



**Fig. 1.** HRCT in 2013 and 2014

ease course in IPF and may have an effect on a patients' suitability for transplantation although the presence of multiple comorbidities ultimately influences survival and opportunity for transplantation (1).

## REFERENCE

1. Hyldgaard C, Hilberg O, Bendstrup E. How does comorbidity influence survival in idiopathic pulmonary fibrosis? *Respir Med* 2014 Apr; 108 (4): 647-53.